HOME >> BIOLOGY >> NEWS
Colorado State microbiologists help identify cell membrane substance that could,,'boost' vaccines for tuberculosis, other diseases

FORT COLLINS--Two Colorado State University microbiologists have helped identify a substance produced by the tuberculosis bacterium that triggers an immune response in the human body.

The finding suggests that the substance in combination with vaccines could serve to enhance the ability of the bodies' immune response to fight tuberculosis and other microbial infections.

A report of the finding, published Friday in the journal Science, includes among its authors Patrick Brennan, professor of microbiology, and John Belisle, assistant professor of microbiology.

Working with researchers from UCLA and a number of other institutions, the Colorado State investigators undertook the specific task of identifying the lipoprotein, a molecule combining fat-like materials with protein, found in the cell walls of Mycobacterium tuberculosis.

"Our role (at Colorado State) was actually in isolating the lipoprotein molecule from the tuberculosis bacilli, purifying it and then working closely with the UCLA group to show that this is what was stimulating interleukin-12 production," Belisle said. Interleukin-12, produced by the human body, initiates a cascade of chemicals that activate production of more white blood cells to combat invading bacteria.

"In practical terms, we think we may have isolated a natural adjuvant (vaccine booster) that can be included with subunit vaccines (those made with parts of bacteria, such as proteins) to push the immune system in the right direction," Belisle said.

By isolating and concentrating the lipoprotein producing the strongest reaction, Belisle and Brennan hope to add it to vaccines under development, including one by a Colorado State research team led by microbiologist Ian Orme. The combined effect should provide immunity against the growing threat of tuberculosis, which is affecting urbanites in underdeveloped areas, prison populations and those with alread
'"/>

Contact: David Weymiller
dweymiller@vines.colostate.edu
970-491-6851
Colorado State University
30-Jul-1999


Page: 1 2 3

Related biology news :

1. Colorado River Conference Aug. 26
2. Hidden cost of Colorado River diversions is $2.4 billion annually
3. Earstones tell fishes tale of early life in the Colorado River estuary
4. U. of Colorado professor pioneering tissue engineering from knees to hearts to brains
5. University of Colorado archaeologist, colleagues hot on the trail of ancient Persian warships
6. U. of Colorado team developing Flu Chip for fast, accurate diagnosis
7. Microbes active in Colorado snows fuel tundra ecosystem
8. New Colorado U. study shows increase in fungal metabolism under the snow
9. Changing global nitrogen cycle impacting human health, says Colorado University-led study
10. U. of Colorado scientists discover four new kingdoms of life
11. U.of Colorado researchers solve molecular structure involved with heart disease

Post Your Comments:
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
(Date:3/5/2015)... NORWALK, Conn. , March 5, 2015 /PRNewswire/ ... Network , a leading online community to ... understanding of the newest information available regarding the ... coverage of kidney cancer. March is ... there are very few effective adjuvant treatment options ...
(Date:3/5/2015)... March 5, 2015  In response to the incorrect ... Miami, FL on February 12, 2015. Impeto ... strong financial health and their SUDOSCAN® devices have been ... indicated. Furthermore, Impeto prefers to have the courts decide this ... more than 40 articles written by Key Opinion Leaders, ...
(Date:3/5/2015)... 05, 2015 The next implants made ... the CE mark (European) approval. The CE mark is ... Association (EFTA) and the European Union. Following the Class ... granted to implants supplied by the Turkey-based company Osimplant ... , Osimplant's Cervical Expandable Bladed HA PEEK Cage line ...
(Date:3/4/2015)... INCLINE VILLAGE, Nev. , March 4, 2015 PDL ... that the adjusted conversion rate for the: , ... Notes), is 174.8506 shares of common stock per $1,000 principal ... The conversion rate for the note is adjusted ... be paid on March 12, 2015, to all stockholders who own ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
Cached News: